Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension

Inotek Pharmaceuticals Corporation (the “Company” or “Inotek”) (NASDAQ:ITEK), a clinical-stage-coach biopharmaceutical company focused on the finding, development and commercialization of therapies in quest of ocular diseases, today announced the Journal of Ocular Pharmacology and Therapeutics has newly published the results from a Phase 2 study of the Company’s have the ~ of product candidate, trabodenoson, in patients through primary open-angle glaucoma (POAG) or ocular hypertension (OHT).

Data from this essay demonstrated that trabodenoson was well tolerated and had signifying reductions in intraocular pressure (IOP). Trabodenoson is a primeval-in-class selective adenosine mimetic designed to grow less IOP at the trabecular meshwork (the illegitimate site of IOP regulation), and is generally in Phase 3 development.

“Patients with glaucoma have limited therapeutic options that make provision reduction in intraocular pressure with moral works tolerability,” commented David P. Southwell, President and Chief Executive Officer of Inotek. “The premises from this Phase 2 trial establish the potential of trabodenoson to procure clinically meaningful reductions in IOP with a favorable safety profile.”

The study article entitled “A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma,” demonstrates that ocular doses of trabodenoson, from 50 to 500 mcg, were well tolerated and showed a drench-related reduction in IOP that was statistically signifying and clinically relevant at 500 mcg in patients through POAG or OHT. No clinically meaningful ocular or systemic border effects were identified. Additionally, there were ~t any trabodenoson-related discontinuations in the exertion.

“These favorable safety and energy data are consistent with other clinical trials of trabodenoson in glaucoma. Importantly, these results on these terms guidance for the design of the ongoing pivotal Phase 3 (MATrX-1) trial, from which we anticipate topline data in the fourth furnish with ~s of 2016,” said Rudolf Baumgartner, MD, Chief Medical Officer of Inotek.

About the Phase 2 Study

The Phase 2 study was a multicenter, randomized, double-masked, placebo-controlled, prescribed portion -escalation trial in patients with POAG or OHT. IOP was assessed using Goldmann applanation tonometry. The primeval efficacy endpoint was mean IOP regular over 12 hours versus placebo. Subjects were 18–77 years long-cultivated and diagnosed with POAG or OHT with a baseline IOP ≥ 24 mmHg (forward no IOP lowering therapy). Exclusion criteria included beyond all others-corrected visual acuity worse than 20/60 in any one eye, advanced glaucoma and other factors.


ARTICLE REFERENCE: Journal of Ocular Pharmacology and Therapeutics. March 2016, onward of print. doi:10.1089/jop.2015.0148. Study authors; Jonathan S. Myers1, Kenneth N. Sall2, Harvey DuBiner3, Natanya Slomowitz4, William McVicar4, Cadmus C. Rich4 and Rudolf A. Baumgartner4.

1Wills Eye Hospital, Philadelphia, Pennsylvania

2Sall Research Medical Center, Artesia, California

3Eye Care Centers Management, Inc., Morrow, Georgia

4Inotek Pharmaceuticals Corporation, Lexington, Massachusetts

About Inotek Pharmaceuticals Corporation

Inotek is a clinical-point biopharmaceutical company focused on the finding out, development and commercialization of therapies in spite of glaucoma and other eye diseases. The Company’s precede product candidate, trabodenoson, is a ~ and foremost-in-class selective adenosine mimetic commonly in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to render up the eye’s natural pressure have the direction of mechanism. Additionally, the Company is evaluating the possible for selective adenosine mimetics to accost optic neuropathies and other degenerative retinal diseases. For more information, please visit

Forward-Looking Statements

This throng release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These at the fore part-looking statements often include words such as “believe,” “rely upon,” “anticipate,” “intend,” “contrive,” “estimate,” “strive after,” “will,” “may” or resembling expressions. Accordingly, you should not fortress undue reliance on these forward-looking statements. All such statements speak only as of the be reckoned made, and the Company undertakes not at all obligation to update or revise publicly somewhat forward-looking statements, whether as a end of new information, future events or else.

View source version on

Sildenafil Citrate habitual to reunite your lost durability and scope to have male organ erectile sexual stimulation.

Recent Comments